Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Joerg Herrmann MD
Joerg Herrmann MD Associate Editor
Ileana Piña MD, MPH, FAHA, FACC
Ileana L. Piña MD, MPH, FAHA, FACC Advisory Board
Douglas Zipes MD
Douglas P. Zipes MD Editor-in-Chief
See All Experts
featured
Published in Cardiology

Journal Scan / Research · April 27, 2017

Inhaled Beta2-Agonist/Corticosteroid Treatment Does Not Increase Cardiovascular Risk in Patients With COPD

Heart (British Cardiac Society)

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Mark Dransfield MD

Heart (British Cardiac Society)
Cardiovascular Outcomes With an Inhaled Beta2-Agonist/Corticosteroid in Patients With COPD at High Cardiovascular Risk
Heart 2017 Apr 17;[EPub Ahead of Print], RD Brook, JA Anderson, PM Calverley, BR Celli, C Crim, MA Denvir, S Magder, FJ Martinez, S Rajagopalan, J Vestbo, J Yates, DE Newby

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated